Danazol therapy for idiopathic thrombocytopenic purpura (ITP)

Usefulness of abdominal ultrasonography with studies of the intestinal loops in Turner syndrome patients.

Journal of ultrasound·2014

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

Oncology reports·2011

Advanced breast-cancer - a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-Fluorouracil.

Oncology reports·2011

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

International journal of oncology·2011

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors.

International journal of oncology·2011

Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Haematologica·2026

Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

Haematologica·2026

Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

Haematologica·2026

Normal platelet function in a patient with ARHGEF1 deficiency.

Haematologica·2026

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Haematologica·2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Haematologica·2026

Reversing Dysfunction of CCR9+ Regulatory T Cells by Targeting the IL-21/IL-17 Axis Improves Type 1 Diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026

The Patient With Multiple Alloantibodies: A Systematic Strategy for Antibody Identification and Transfusion Management.

Case reports in immunology·2026

Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.

Frontiers in immunology·2026

Global development of bispecific antibodies in oncology: a bibliometric analysis of geographic disparities, collaborative models, and emerging translational strategies.

Frontiers in immunology·2026

Quality improvement project - Implementation of subcutaneous immunoglobulin in patients with haematological disorders and secondary immunodeficiency.

Therapeutic advances in hematology·2026

Development of immune-related adverse events is associated with improved survival outcomes in cancer patients receiving immune checkpoint inhibitors.

Frontiers in immunology·2026

Related Experiment Videos

Danazol therapy for idiopathic thrombocytopenic purpura (ITP)

Related Concept Videos

Usefulness of abdominal ultrasonography with studies of the intestinal loops in Turner syndrome patients.

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

Advanced breast-cancer - a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-Fluorouracil.

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors.

Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

Normal platelet function in a patient with ARHGEF1 deficiency.

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Reversing Dysfunction of CCR9+ Regulatory T Cells by Targeting the IL-21/IL-17 Axis Improves Type 1 Diabetes.

The Patient With Multiple Alloantibodies: A Systematic Strategy for Antibody Identification and Transfusion Management.

Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.

Global development of bispecific antibodies in oncology: a bibliometric analysis of geographic disparities, collaborative models, and emerging translational strategies.

Quality improvement project - Implementation of subcutaneous immunoglobulin in patients with haematological disorders and secondary immunodeficiency.

Development of immune-related adverse events is associated with improved survival outcomes in cancer patients receiving immune checkpoint inhibitors.

Related Experiment Videos

Danazol therapy for idiopathic thrombocytopenic purpura (ITP)

Related Concept Videos

Related Articles